BENDEKA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BENDEKA (BENDEKA).
Bendamustine is a bifunctional mechlorethamine derivative with alkylating and antimetabolite properties. It forms cross-links between DNA strands, leading to DNA synthesis inhibition and apoptosis. The exact mechanism also involves activation of p53-dependent and p53-independent stress pathways, and inhibition of mitotic checkpoints.
| Metabolism | Bendamustine is extensively metabolized via hydrolysis to monohydroxy and dihydroxy metabolites (major pathways) and via CYP1A2 to minor metabolites (N-demethylation). The hydrolysis metabolites are inactive; CYP1A2 metabolites have low activity. Glutathione conjugation also occurs. |
| Excretion | Primarily renal excretion (approximately 50% as unchanged drug and metabolites); biliary/fecal elimination is minor (<5%). |
| Half-life | Terminal elimination half-life is approximately 40 minutes for bendamustine; active metabolite (gamma-hydroxybendamustine) has half-life of about 3 hours. Clinical context: short half-life allows for rapid clearance, but requires frequent dosing. |
| Protein binding | Approximately 94-96% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 20-25 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Not orally bioavailable; administered only intravenously. Absolute bioavailability not applicable. |
| Onset of Action | Intravenous: clinical effect typically observed within 1-2 hours post-infusion. |
| Duration of Action | Duration of myelosuppression and other effects typically lasts 2-4 weeks; clinical response may persist several months with repeated cycles. |
120 mg/m2 intravenously infused over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
| Dosage form | SOLUTION |
| Renal impairment | For creatinine clearance 30-50 mL/min: reduce dose to 90 mg/m2. For creatinine clearance <30 mL/min: not recommended. |
| Liver impairment | For Child-Pugh A (mild): no dose adjustment. For Child-Pugh B (moderate): reduce dose to 90 mg/m2. For Child-Pugh C (severe): not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; monitor for toxicity more frequently due to increased sensitivity and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BENDEKA (BENDEKA).
| Breastfeeding | No data on presence in human milk. Due to potential for serious adverse reactions in breastfed infants (e.g., myelosuppression, carcinogenesis), breastfeeding is not recommended during treatment and for at least 1 week after last dose. M/P ratio not available. |
| Teratogenic Risk | Bendamustine is embryotoxic and teratogenic in animal studies. In pregnant women, use is contraindicated unless clearly necessary. First trimester: highest risk of major malformations and miscarriage. Second and third trimesters: risk of fetal growth restriction, myelosuppression, and potential carcinogenesis. |
■ FDA Black Box Warning
BENDEKA should not be used in patients with severe renal impairment (creatinine clearance <30 mL/min) or severe hepatic impairment (AST/ALT >2.5× ULN or bilirubin >1.5× ULN).
| Serious Effects |
["Hypersensitivity to bendamustine or mannitol","Severe renal impairment (CrCl <30 mL/min)","Severe hepatic impairment (AST/ALT >2.5× ULN or bilirubin >1.5× ULN)"]
| Precautions | ["Myelosuppression: neutropenia, thrombocytopenia, anemia; monitor blood counts","Infusion reactions: fever, chills, pruritus, hypotension; premedicate with antihistamines and corticosteroids if severe","Infections: increased risk, including reactivation of tuberculosis and viral infections","Secondary malignancies: myelodysplastic syndrome, acute myeloid leukemia","Tumor lysis syndrome: risk in patients with high tumor burden; ensure adequate hydration and monitor uric acid","Renal toxicity: acute renal failure; monitor renal function","Stevens-Johnson syndrome/TEN: severe cutaneous reactions; discontinue if suspected","Hepatotoxicity: elevation of liver enzymes; monitor hepatic function","Extravasation: local tissue injury; avoid extravasation"] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Monitor complete blood counts weekly during pregnancy. Assess fetal growth by ultrasound every 4-6 weeks. Consider fetal echocardiography if exposure in first trimester. Monitor for signs of infection and bleeding. |
| Fertility Effects | Bendamustine is cytotoxic and may cause gonadal suppression, amenorrhea, and azoospermia. Potential for irreversible infertility in both male and female patients. |
| Avoid grapefruit and grapefruit juice. Maintain adequate hydration to prevent tumor lysis syndrome. No specific food restrictions otherwise. |
| Clinical Pearls | BENDEKA (bendamustine hydrochloride) is a nitrogen mustard alkylating agent used for CLL and indolent B-cell NHL. Administer as IV infusion over 30 minutes; premedicate with antiemetics. Monitor for infusion reactions, myelosuppression (especially lymphopenia and neutropenia), and tumor lysis syndrome. Avoid live vaccines during treatment. Dose reduction required for moderate hepatic impairment (bilirubin 1.5-3× ULN). Renal impairment (CrCl <40 mL/min) increases toxicity. Contraindicated in severe hepatic impairment (bilirubin >3× ULN). |
| Patient Advice | BENDEKA is given as an intravenous infusion over 30 minutes, usually for several cycles. · Common side effects include nausea, vomiting, low blood counts, fever, and fatigue. · Report signs of infection (fever, chills), bleeding, or unusual bruising immediately. · Avoid live vaccines (e.g., flu nasal spray, MMR) while on this medication. · Do not drive or operate machinery if you experience dizziness or confusion. · Use effective contraception during treatment and for 3 months after the last dose. |